<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03091933</url>
  </required_header>
  <id_info>
    <org_study_id>CR-MIHA-001</org_study_id>
    <nct_id>NCT03091933</nct_id>
  </id_info>
  <brief_title>Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)</brief_title>
  <acronym>GLIDE</acronym>
  <official_title>An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Anti-minor Histocompatibility Complex (MiHA) Donor T-lymphocytes Expanded ex Vivo, in Patients With a Hematologic Malignancy, With Molecular or Clinical Relapse After Hematopoietic Stem Cell Transplantation From a Matched Donor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ciusss de L'Est de l'Île de Montréal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ciusss de L'Est de l'Île de Montréal</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety of infusing an anti-MiHA T cell line in patients
      suffering from an hematologic malignancy that has relapsed following hematopoietic stem cell
      transplantation from a matched donor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The GLIDE-201/44 trial primarily aims to test the safety of anti-MiHA T cell line in patients
      suffering from an hematologic malignancy that has relapsed following hematopoietic stem cell
      transplantation from a matched donor. The anti-MiHA T cell lines are derived from the matched
      donor for the patient, the original donor for a given patient. Both the patient and the
      matched donor will undergo screening to determine the expression of targetable MiHAs. Upon
      identification of the target MiHAs, donor cells will be collected through apheresis and
      primed against the selected MiHA. In this setting, the GLIDE 201/44 product will be
      cryopreserved, thawed and administered as a single infusion at a target dose of 4x10E+07
      viable T cells/m2 (range of dose is 0.4 4x10E+07 viable T cells/m2). A second infusion can be
      offered to the patients after an observation period of 42 days upon clinical evaluation by
      the treating physician. In the absence of secondary adverse events following the initial
      infusion, a second infusion of the GLIDE 201/44 product could be administered at a dose level
      up to 3-5 fold the original dose.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>exploratory, open-label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-hematologic toxicity related to GLIDE post injection</measure>
    <time_frame>6 months</time_frame>
    <description>No death or other toxic events directly related to GLIDE injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response of hematologic malignancy (acute leukemia (ALL, AML, biphenotypic), CLL, HL, NHL, MM or MDS) post-injection</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Disease progression following GLIDE injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of acute and chronic graft versus host disease (GvHD)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Progression (if any) or induction of GvHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of GLIDE in the host and homing to peripheral blood, bone marrow and other tissues</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Monitoring of GLIDE product persistence in host</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-Relapse mortality (NRM)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Time to deaths without relapse/recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-incidence (RI)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Time to relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Time to death, irrespective of the cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>It is time to any of the following: OS, RI, NRM, Time to relapse, Relapse free survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hematologic Cancer</condition>
  <condition>Relapse Leukemia</condition>
  <condition>Relapsed Adult ALL</condition>
  <condition>Relapsed Adult AML</condition>
  <condition>Relapsed CLL</condition>
  <condition>Relapsed Non Hodgkin Lymphoma</condition>
  <condition>Relapsed Hodgkin's Lymphoma</condition>
  <condition>Relapsed Myelodysplastic Syndromes</condition>
  <condition>Relapsed Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>GLIDE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLIDE single infusion at a target dose of 4x107 viable T-cells/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GLIDE</intervention_name>
    <description>Gudide Lymphocyte by Immunopeptide Derived Expansion (GLIDE) is an anti- Minor histocompatibility (MiHA) cell line</description>
    <arm_group_label>GLIDE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior allogeneic HLA-matched stem cell transplantation

          -  Any of the following hematologic malignancies:

          -  Acute myeloid leukemia (AML)

          -  Acute lymphoblastic leukemia (ALL)

          -  Biphenotypic leukemia

          -  Chronic lymphoblastic leukemia (CLL)

          -  Hodgkin Lymphoma

          -  Non-Hodgkin Lymphoma (NHL)

          -  Multiple Myeloma (MM)

          -  Myelodysplastic syndrome (MDS)

          -  Presence of HLA2:01 and / or HLA44:02 and / or HLA-B*44:03, HLA-A*01:01; HLA-A*03:01;
             HLA-A*11:01;HLA A*24:02; HLA-A*29:02; HLA-A*32:01; HLA-B*07:02; HLA-B*08:01; HLA
             B*13:02; HLA-B*14:02; HLA-B*15:01; HLA-B*18:01; HLA-B*27:05; HLA B*35:01; HLA-B*40:01;
             or HLA-B*57:01

          -  At least 6 months after allogeneic hematopoietic stem cell transplantation

          -  Presence of detectable malignant disease post-transplantation in the form of
             molecular, cytogenetic or hematologic relapse of the malignant disorder.

          -  Eligible to receive cytoreductive chemotherapy

          -  Original stem cell donor available for leukocyte donation.

          -  ECOG performance status ≤2.

          -  Ability to provide written consent.

          -  Accessible for treatment and follow up.

          -  Presence of a targetable MiHA based on exome sequencing of the patient and donor

        Exclusion Criteria:

          -  Active acute GVHD &gt; grade I

          -  Prior grade III-IV acute GVHD within the last year

          -  Uncontrolled chronic GVHD

          -  Prior administration of donor lymphocyte infusion (DLI)

          -  Use of T-cell depleting antibodies in the previous 30 days

          -  Treatment with immune suppressors (oral or parenteral steroids corresponding to a dose
             of prednisone greater than 7.5 mg/day, calcineurine inhibitors, rapamycin,
             mycophenolate mofetil, etc) during the last 30 days.

          -  Uncontrolled active infection

          -  Uncontrolled central nervous system involvement by leukemia cells (blasts).

          -  AST or ALT &gt; 2.5 x ULN (CTCAE grade 2)

          -  Bilirubin &gt; 1.5 x ULN (CTCAE grade 2)

          -  Creatinine clearance &lt; 50 mL/min

          -  Positive test for human immunodeficiency virus (HIV)

          -  Positive pregnancy test (women of childbearing age only)

          -  Lactating women: the safety of this therapy on breast milk is not known.

          -  Estimated probability of surviving less than 3 months

          -  Known allergy to any of the components of GLIDE (e.g., dimethyl sulfoxide)

          -  Intercurrent illness or medical condition precluding safe administration of the
             planned protocol treatment or required follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis-Claude Roy, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIUSSS d l'Est-de-l'Île-de-Montréal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Sébastien Delisle, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIUSSS d l'Est-de-l'Île-de-Montréal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Silvy Lachance, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIUSSS d l'Est-de-l'Île-de-Montréal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Guy Némorin, PhD</last_name>
    <phone>(514) 252-3400</phone>
    <phone_ext>6247</phone_ext>
    <email>jgnemorin@centrec3i.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stéphanie Thiant, PhD</last_name>
    <phone>(514) 252-3400</phone>
    <phone_ext>4681</phone_ext>
    <email>sthiant.hmr@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CIUSSS d l'Est-de-l'Île-de-Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Guy Némorin, PhD</last_name>
      <phone>514-252-3400</phone>
      <phone_ext>6247</phone_ext>
      <email>jgnemorin@centrec3i.com</email>
    </contact>
    <contact_backup>
      <last_name>Stéphanie Thiant, PhD</last_name>
      <phone>214-252-3400</phone>
      <phone_ext>4681</phone_ext>
      <email>sthiant.hmr@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Denis-Claude Roy, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Sébastien Delisle, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvy Lachance, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>allogeneic hematopoietic stem cell transplantation</keyword>
  <keyword>relapsed hematopoietic malignancy</keyword>
  <keyword>HLA matched donor</keyword>
  <keyword>minor histocompatibilty antigen (MiHA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcome measures will be made available within 6 months of study end</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

